Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Caroen

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
International Journal of Molecular Sciences|December 11, 2022
What Exactly Is Inflammation (and What Is It Not?)Bryan Oronsky, Scott Caroen, Tony Reid
American Journal of Cancer Research|May 9, 2022
The small molecule NLRP3 inhibitor RRx-001 potentiates regorafenib activity and attenuates regorafenib-induced toxicity in mice bearing human colorectal cancer xenograftsTony Reid, Bryan Oronsky, Nacer Abrouk, et al.
International Journal of Medical Sciences|October 14, 2022
Superficial Venous-Associated Inflammation from Direct IV Administration of RRx-001 in RatsScott Caroen, Bryan Oronsky, Tony Reid, et al.
Life Sciences in Space Research|November 6, 2022
RRx-001 and the "Right stuff": Protection and treatment in outer spaceBryan Oronsky, Scott Caroen, Nacer Abrouk, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 8, 2022
Could nucleocapsid be a next-generation COVID-19 vaccine candidate - author's replyBryan Oronsky, Christopher Larson, Scott Caroen, et al.
Journal of Investigative Medicine High Impact Case Reports|March 20, 2018
A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum DoubletHope Cottrill, Stephanie Cason, Scott Caroen, et al.
Frontiers in Oncology|June 21, 2023
A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastomaHoward Fine, Tony Reid, Scott Caroen, et al.
Frontiers in Oncology|June 14, 2023
RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonistBryan Oronsky, Lori Takahashi, Richard Gordon, et al.
Molecular Cancer Therapeutics|February 1, 2024
Predicting the Abscopal Phenomenon-Letter to the EditorAnthony P Conley, Bryan Oronsky, Scott Caroen, et al.
Journal for Immunotherapy of Cancer|October 26, 2024
TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistanceTony R Reid, Bryan Oronsky, Jeannie Williams, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
International Journal of Molecular Sciences|December 11, 2022
What Exactly Is Inflammation (and What Is It Not?)Bryan Oronsky, Scott Caroen, Tony Reid
American Journal of Cancer Research|May 9, 2022
The small molecule NLRP3 inhibitor RRx-001 potentiates regorafenib activity and attenuates regorafenib-induced toxicity in mice bearing human colorectal cancer xenograftsTony Reid, Bryan Oronsky, Nacer Abrouk, et al.
International Journal of Medical Sciences|October 14, 2022
Superficial Venous-Associated Inflammation from Direct IV Administration of RRx-001 in RatsScott Caroen, Bryan Oronsky, Tony Reid, et al.
Life Sciences in Space Research|November 6, 2022
RRx-001 and the "Right stuff": Protection and treatment in outer spaceBryan Oronsky, Scott Caroen, Nacer Abrouk, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 8, 2022
Could nucleocapsid be a next-generation COVID-19 vaccine candidate - author's replyBryan Oronsky, Christopher Larson, Scott Caroen, et al.
Journal of Investigative Medicine High Impact Case Reports|March 20, 2018
A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum DoubletHope Cottrill, Stephanie Cason, Scott Caroen, et al.
Frontiers in Oncology|June 21, 2023
A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastomaHoward Fine, Tony Reid, Scott Caroen, et al.
Frontiers in Oncology|June 14, 2023
RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonistBryan Oronsky, Lori Takahashi, Richard Gordon, et al.
Molecular Cancer Therapeutics|February 1, 2024
Predicting the Abscopal Phenomenon-Letter to the EditorAnthony P Conley, Bryan Oronsky, Scott Caroen, et al.
Journal for Immunotherapy of Cancer|October 26, 2024
TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistanceTony R Reid, Bryan Oronsky, Jeannie Williams, et al.
Pageof 6